Diagnostic Performance of the New Free Light Chain Ratio in Systemic Amyloidosis

JACC. CardioOncology · Published 2025-09-11 · DOI 10.1016/j.jaccao.2025.07.012

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.jaccao.2025.07.012

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2025

Related articles

• The light chain hunt: appraising assays in AL amyloidosis · Blood Advances · 2026 · Cites or is cited by this article
• CRISPR/Cas9 Screens Implicate RARA and SPNS1 in Doxorubicin Cardiotoxicity · JACC. CardioOncology · 2026 · Same journal
• Sacubitril/Valsartan in Anthracycline-Treated Patients · JACC. CardioOncology · 2026 · Same journal
• Major Adverse Cardiovascular Events and Cardiac Dysfunction in Patients With Acute Leukemia · JACC. CardioOncology · 2026 · Same journal
• Screened But Unproven · JACC. CardioOncology · 2026 · Same journal
• Treatment and Outcomes in Myocardial Infarction and Cancer—A German Real-Life Analysis · JACC. CardioOncology · 2026 · Same journal
• Sotatercept for the Treatment of Myeloproliferative Neoplasm–Associated Group 5 Pulmonary Hypertension · JACC. CardioOncology · 2026 · Same journal
• The Promise and Pitfalls of TTR Stabilization Assays in ATTR-CM · JACC. CardioOncology · 2026 · Same journal
• Elevated Plasma IL-18 Levels During Chemotherapy Treatment for Breast Cancer, Exercise Capacity, and Physical Activity · JACC. CardioOncology · 2026 · Same journal
• Proactive Surveillance for ICI Cardiotoxicity · JACC. CardioOncology · 2026 · Same journal